Evidence map›Paper›PMID 27222470›Full record

ArticlemBio2016

Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.

Martin Gengenbacher, Natalie Nieuwenhuizen, Alexis Vogelzang, Haipeng Liu, Peggy Kaiser, Stefanie Schuerer, Doris Lazar, Ina Wagner, Hans-Joachim Mollenkopf, Stefan H E Kaufmann

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 83 citations in OpenAlex.

  1. Trial
  2. Construction and characterization of novelInfection and immunity · 2026
    Article
  3. HowVaccines · 2026
    Review
  4. Review
  5. Article
  6. Cell death pathways in response toInfection and immunity · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. The Immunogenicity and Safety ofMicroorganisms · 2023
    Article
  18. Virulence Factors ofPathogens (Basel, Switzerland) · 2023
    Review
  19. Review
  20. Structure of mycobacterial respiratory complex I.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Martin GengenbacherDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany Department of Microbiology and Immunology, National University of Singapore, Yong Loo Lin School of Medicine, Singapore.
Natalie NieuwenhuizenDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Alexis VogelzangDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Haipeng LiuDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Peggy KaiserDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Stefanie SchuererDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Doris LazarDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Ina WagnerMax Planck Institute for Infection Biology, Core Facility Genomics/Microarray, Berlin, Germany.
Hans-Joachim MollenkopfMax Planck Institute for Infection Biology, Core Facility Genomics/Microarray, Berlin, Germany.
Stefan H E KaufmannDepartment of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany kaufmann@mpiib-berlin.mpg.de.
Max Planck Institute for Infection Biology · DENational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe current tuberculosis (TB) vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), provides insufficient protection against pulmonary TB. Previously, we generated a listeriolysin-expressing recombinant BCG strain, which to date has successfully completed phase I and phase IIa clinical trials. In an attempt to further improve efficacy, we deleted the antiapoptotic virulence gene nuoG, encoding NADH dehydrogenase 1 subunit G, from BCG ΔureC::hly In vitro, deletion of nuoG unexpectedly led to strongly increased recruitment of the autophagosome marker LC3 to the engulfed vaccine, suggesting that nuoG also affects xenophagic pathways. In mice, BCG ΔureC::hly ΔnuoG vaccination was safer than BCG and improved protection over that of parental BCG ΔureC::hly, significantly reducing TB load in murine lungs, ameliorating pulmonary pathology, and enhancing immune responses. Transcriptome analysis of draining lymph nodes after vaccination with either BCG ΔureC::hly or BCG ΔureC::hly ΔnuoG demonstrated earlier and stronger induction of immune responses than that with BCG SSI and suggested upregulation of inflammasome activation and interferon-induced GTPases. In summary, BCG ΔureC::hly ΔnuoG is a promising next-generation TB vaccine candidate with excellent efficacy and safety. IMPORTANCE: Autophagy and apoptosis are fundamental processes allowing cells to degrade their components or kill themselves, respectively. The immune system has adopted these mechanisms to eliminate intracellular pathogens. Residing in host cells, the causative agent of tuberculosis, Mycobacterium tuberculosis, has evolved strategies to set cellular programs of autophagy and apoptosis "on hold." The mycobacterial gene nuoG was found to prevent host cell apoptosis. We have deleted nuoG in the live vaccine candidate BCG ΔureC::hly, which is in phase II clinical development, to leave cellular apoptosis "on go" upon immunization. In preclinical models, this strategy boosted immunity and improved protection from M. tuberculosis infection. Unexpectedly, we obtained compelling evidence that mycobacterial nuoG facilitates inhibition of autophagic pathways, suggesting a new role for this gene in the host-pathogen interplay in tuberculosis.

Indexed as

Gene DeletionAnimalsBacterial LoadBacterial ProteinsBCG VaccineElectron Transport Complex IGene Expression ProfilingInflammasomesLungLymph NodesMiceMycobacterium bovisTuberculosis, PulmonaryVaccinationBacterial ProteinsBCG VaccineElectron Transport Complex IInflammasomes

Identifiers

PMID27222470
PMCPMC4895111
OpenAlexW2408473116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.